Jump to content

CVC worldwide clinical research network


Recommended Posts

Celldex Therapeutics and Ludwig Institute for Cancer Research Announce Cancer Antigen License and Clinical Research Collaboration

Multi-Year Clinical Collaboration To Focus on Series of Tumor-Associated


PHILLIPSBURG, N.J., Oct. 23 /PRNewswire/ -- Celldex Therapeutics, Inc.

and the international Ludwig Institute for Cancer Research (LICR) today

announced a multi-year clinical research collaboration focusing on a series

of tumor- associated antigens (TAAs) for use in Celldex's Antigen

Presenting Cell (APC) Targeting Technology. These antigens, previously

identified and characterized immunologically by LICR, will add

substantially to new Celldex development programs for a range of cancer

types. Three of these antigens (NY-ESO-1, MAGE3, and MelanA) are being

studied in non-small cell lung, ovarian, and bladder cancers, as well as

melanoma, in an extended series of Phase I/II programs conducted by the

LICR and its collaborators.

The collaboration will encompass the development of next-generation

immunotherapies using Celldex's proprietary APC targeting monoclonal

antibodies and the Ludwig TAAs. These development candidates will be

available to LICR for evaluation within the Cancer Vaccine Collaborative

(CVC) worldwide clinical research network, a collaboration between the LICR

and the leading cancer charity, the New York-based Cancer Research


"The Celldex technology is a novel approach to inducing a patient's

immune system to fight cancer," said Jonathan C.A. Skipper, Ph.D.,

Executive Director for Intellectual Property & Technology Licensing at the

Ludwig Institute. "This system has the potential to deliver TAAs precisely

to the right cells, in contrast to other TAA delivery technologies. The CVC

is very much looking forward to exploring this promising TAA delivery

approach in its early-phase clinic trials."

"We are pleased to announce this agreement with the Ludwig Institute,

an acknowledged academic leader in the field of cancer immunotherapy, as a

key addition to our cancer development programs," said Robert Burns, Ph.D.,

President and CEO of Celldex Therapeutics. "With the licensing of this

important portfolio of clinically-validated cancer antigens, we strengthen

our commitment to developing innovative immunotherapies against a wide

variety of oncology targets, employing our unique APC targeted delivery


About the Ludwig Institute for Cancer Research

The Ludwig Institute for Cancer Research (LICR) is the largest

international academic institute dedicated to understanding and controlling

cancer. Headquartered in New York, and with one Center for Clinical

Sciences and nine Branches in seven countries, the scientific network that

is LICR spans the globe. LICR has developed an impressive portfolio of

reagents, knowledge, expertise, and intellectual property, and has also

assembled the personnel, facilities, and practices necessary to patent,

clinically evaluate, license, and thus translate, the most promising

aspects of its own laboratory research into cancer therapies.

About the Cancer Research Institute

The Cancer Research Institute (CRI) is a non-profit organization that

funds research aimed at furthering the development of immunological

approaches to the diagnosis, treatment, and prevention of cancer. CRI's

research programs are designed to recognize and support those researchers

around the world who are focused on this area. Today, CRI provides funding

at every level of scientific inquiry, from coordinated clinical trials to

the most basic research, and supports scientists at all career levels.

About the APC Targeting Technology

The foundation of Celldex Therapeutics' Antigen Presenting Cell (APC)

Targeting Technology is the ability of the Company's proprietary

antibodies to deliver agents to specific cellular components of the immune

system. In particular, Celldex has developed antibodies that possess unique

characteristics for delivering antigens directly to professional APCs,

dendritic cells and macrophages that we believe will generate rapid and

heightened immune responses. By effectively targeting antigens (or other

agents) to these specialized cells of the immune system, Celldex's product

candidates can transform even weakly immunogenic antigens into effective

targets for immunotherapy, and circumvent the need for individualized ex

vivo dendritic cell manipulation.

About Celldex Therapeutics, Inc.

Celldex Therapeutics, Inc. is a biotechnology company focused on

developing fully human antibody-based products that target and stimulate

the body's immune system for the treatment of cancer, infectious and

autoimmune diseases. The Company's lead product, CDX-110, is scheduled to

have entered a definitive Phase 2/3 clinical trial for the treatment of

newly diagnosed glioblastoma by early 2007. Celldex has three product

candidates already in or about to enter clinical development targeting

multiple cancers as well as Hepatitis B. Four additional product candidates

are in preclinical development for cancer and autoimmune disease. Celldex's

proprietary technology platform uses fully human monoclonal antibodies

administered directly to patients to target and stimulate dendritic cells -

key cells within the immune system. Celldex was formed in 2004 as a

spin-out from Medarex, Inc (Nasdaq: MEDX). The Company is headquartered in

Phillipsburg, New Jersey and also has R&D operations in Cambridge, UK. For

more information, please visit the website:

http://www.celldextherapeutics.com .

SOURCE Celldex Therapeutics, Inc.


Related links:


Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.